基因型指导华法林给药与传统给药策略的系统综述与荟萃分析
该系统综述与荟萃分析纳入18项随机对照试验,比较基因型指导华法林给药与传统给药策略。基因型指导组2626例,传统组2604例。结果显示基因型指导可缩短INR达标时间、提高治疗范围内时间比例、降低过度抗凝和出血风险,但未显著改善血栓栓塞或死亡率。
要点
- 基因型指导华法林给药可缩短首次治疗性INR时间2.6天。
- 基因型指导给药降低出血风险(RR 0.82,95%CI 0.69-0.98)。
- 血栓栓塞与死亡率两组无显著差异。
核心结论
- 基因型指导华法林给药较传统策略安全性更好,出血更少,但对血栓栓塞或死亡率无显著获益。
主要发现
- 基因型指导组首次治疗性INR时间平均缩短2.6天(标准误0.3天,P<0.0001,I2=0%)。
- 基因型指导组首次稳定INR时间平均缩短5.9天(标准误2.0天,P<0.01,I2=94%)。
- 基因型指导组治疗范围内时间平均增加3.1%(标准误1.2%,P<0.01,I2=80%)。
- 基因型指导组INR≥4的过度抗凝风险降低(RR 0.87,95%CI 0.78-0.98,P<0.05,I2=0%)。
- 基因型指导组出血风险降低(RR 0.82,95%CI 0.69-0.98,P<0.05,I2=31%)。
关键数值与推荐
- 血栓栓塞风险两组无差异(RR 0.84,95%CI 0.56-1.26,P=0.40,I2=0%)。
- 死亡率两组无差异(RR 1.16,95%CI 0.46-2.91,P=0.76,I2=0%)。
临床怎么用
- 对于需华法林抗凝患者,可考虑基因型指导给药以缩短达标时间并降低出血风险,但需结合临床情况个体化决策。
局限性
- 部分结局异质性较高(首次稳定INR时间I2=94%,治疗范围内时间I2=80%)。
- 平均随访时间较短(64天),长期结局证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Previous trials on the effectiveness of genotype-guided warfarin dosing vs. conventional dosing have been inconclusive. We conducted a systematic review and meta-analysis of randomized trials comparing genotype-guided to conventional dosing strategies. METHODS: PubMed and the Cochrane Library were searched up to 23 October 2017. RESULTS: A total of 76 and 94 entries were retrieved were retrieved from PubMed and the Cochrane Library, respectively. A total of 2626 subjects in the genotype-guided dosing (mean age 63.3 ± 5.8 years; 46% male) and 2604 subjects in the conventional dosing (mean age 64.7 ± 6.1 years; 46% male) groups (mean follow-up duration 64 days) from 18 trials were included. Compared with conventional dosing, genotype-guided dosing significantly shortened the time to first therapeutic international normalized ratio (INR) (mean difference 2.6 days, standard error 0.3 days; P < 0.0001; I2 0%) and time to first stable INR (mean difference 5.9 days, standard error 2.0 days; P < 0.01; I2 94%). Genotype-guided dosing also increased the time in therapeutic range (mean difference 3.1%, standard error 1.2%; P < 0.01; I2 80%) and reduced the risks of both excessive anticoagulation, defined as INR ≥4 [risk ratio (RR) 0.87; 95% confidence interval (CI) 0.78, 0.98; P < 0.05; I2 : 0%), and bleeding (RR 0.82; 95% CI 0.69, 0.98; P < 0.05; I2 31%). No difference in thromboembolism (RR 0.84; 95% CI 0.56, 1.26; P = 0.40; I2 0%) or mortality (RR 1.16; 95% CI 0.46, 2.91; P = 0.76; I2 0%) was observed between the two groups. CONCLUSIONS: Genotype-guided warfarin dosing offers better safety with less bleeding compared with conventional dosing strategies. No significant benefit on thromboembolism or mortality was evident.
引用
- Tse G, Gong M, Li G, et al. Genotype-guided warfarin dosing vs. conventional dosing strategies: a systematic review and meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2018. PMID: 29704269. doi:10.1111/bcp.13621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。